Navigation Links
New myeloma drug shows promise in early testing
Date:6/7/2010

ANN ARBOR, Mich. A drug designed to target cancerous plasma cells appears promising in treating multiple myeloma, a type of blood cancer.

A multi-center study looked at the drug elotuzumab, an antibody which is designed to target CS1, a protein on the surface of malignant plasma cells. The antibody has the potential to attach to malignant plasma cells and eliminates them by an immune mechanism. The early stage trial combined elotuzumab with bortezomib, or Velcade, one of the novel chemotherapies approved to treat multiple myeloma, a cancer that arises in the plasma cells.

"Elotuzumab was found to work in synergy with bortezomib in a pre-clinical model, which served as the basis for this clinic trial. The regimen was well-tolerated, and many patients stayed on it for a long time," says Andrzej Jakubowiak, M.D., Ph.D., director of the Multiple Myeloma Program at the University of Michigan Comprehensive Cancer Center. Jakubowiak presented results of the study at the American Society of Clinical Oncology annual meeting.

The study looked at 28 patients with multiple myeloma that had relapsed or become unresponsive to treatment. Overall, 48 percent responded to the elotuzumab and bortezomib combination and patients' cancer progressed after an average 9.45 months. These numbers are better than in previous studies of patients with less advanced disease treated with bortezomib alone in which 38 percent responded to the treatment and cancer progressed after an average of 6.22 months.

"The study was not designed to evaluate statistical superiority of the combination of elotuzumab and Velcade, but it does appear to support our preclinical evidence that these two drugs work together," Jakubowiak says.

The researchers will next consider a study to compare the combination of elotuzumab and bortezomib against standard therapy to see if the combination achieves better results.


'/>"/>

Contact: Nicole Fawcett
nfawcett@umich.edu
734-764-2220
University of Michigan Health System
Source:Eurekalert

Page: 1

Related medicine news :

1. Drug shows positive responses, low side-effects in multiple myeloma
2. Carfilzomib Safety Data From Ongoing Phase 2b Pivotal Trial in Relapsed and Refractory Multiple Myeloma Show Promising Safety and Tolerability
3. Multiple myeloma patients experience high response rate with new 3-drug combination
4. Experimental targeted therapy shows early promise against medulloblastomas
5. Targeted Therapy Shows Promise Against Deadly Brain Cancer
6. Selenium shows no benefit in prevention of lung cancer
7. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
8. Spending time in nature makes people feel more alive, study shows
9. Targeted immunotherapy shows promise for metastatic breast, pancreatic cancers
10. Prostate Cancer Vaccine Shows Few Side Effects
11. Brief Exercise Reduces Impact of Stress on Cell Aging, UCSF Study Shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Deer Path of Huntley -- a BMA affordable assisted ... 3 p.m. to 4 p.m. on Feb. 13. , The community, ... adults with physical disabilities between the ages of 22 and 64. ... and sweetheart-themed karaoke. , For more information about the event or ...
(Date:1/22/2015)... Va. (PRWEB) January 22, 2015 Liberty University ... Counseling (M.A.) program from the Council for Accreditation ... program, part of Liberty’s Center for Counseling & Family ... founding dean of the university’s new School of Behavioral Sciences. ...
(Date:1/22/2015)... West Hollywood, California (PRWEB) January 22, 2015 The ... 22, 2015 at 10 a.m., to commemorate the 42nd anniversary of ... the United States. , “It’s been 42 years since the Roe ... to choose is still as present as ever,” said City of ...
(Date:1/22/2015)... Chemo Duck Program is pleased to announce the release of the ... with cancer. The Chemo Duck App, available on iTunes for use ... to help children of all ages living with cancer adjust to ... entertained, educated and at ease while waiting for clinic visits or ...
(Date:1/22/2015)... 23, 2015 VogueQueen is a seasoned and ... and many designers are thrilled to have it lead the ... its new collection of prom dresses for the global market. ... the strategic vision and he focuses on continuing the goal ...
Breaking Medicine News(10 mins):Health News:Deer Path of Huntley Affordable Assisted Living to Host Valentine's Day Happy Hour 2Health News:Liberty University's Resident Master’s Counseling Program Receives CACREP Accreditation 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 2Health News:Chemo Duck Launches First App Ever Created for Kids with Cancer 3Health News:VogueQueen Unveils New Designs of Prom Dresses for 2015 2
... Omnicell, Inc. (Nasdaq: OMCL ), a leading provider of system solutions ... 2009 to discuss Omnicell,s Third Quarter 2009 financial results. , ... conference call and webcast, When: October 22, ... Lipps, chairman, president and chief executive officer, ...
... calling on all Virginia restaurants and other workplaces to ... report by the Institute of Medicine (IOM) that concluded ... save lives. , (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , The ... conclusive evidence that secondhand smoke causes heart disease and ...
... , NEW YORK, Oct. 16 It,s open enrollment ... healthcare and other benefits. Sometimes when a serious ... health or disability insurance. Here,s more on making ... battling a major illness. , Listen to this report ...
... SOS Assistance, Inc. today was awarded the contract to provide ... TRICARE Overseas Program. Since 1998, International SOS has supported TRICARE ... receive the highest quality care, no matter where their work ... Rico. , Under this new contract, which includes ...
... MILWAUKEE, Oct. 16 Delays in shipments from vaccine ... Wisconsin to suspend its seasonal flu vaccination clinics throughout ... , The Shoo the Flu & Pneumonia Too! ... The clinics will resume as soon as additional ...
... ... ... than 30 pediatric experts from Children’s National Medical Center will be presenting at ... – 19 in Washington. , , , , ,Children’s pediatric specialists will be discussing many ...
Cached Medicine News:Health News:Omnicell to Release Third Quarter 2009 Earnings Results on October 22 2Health News:Virginia Restaurants Urged to Go Completely Smoke-Free After Major Report Finds Smoke-Free Laws Prevent Heart Attacks 2Health News:Virginia Restaurants Urged to Go Completely Smoke-Free After Major Report Finds Smoke-Free Laws Prevent Heart Attacks 3Health News:International SOS Awarded TRICARE Overseas Program Contract 2Health News:Delays in Vaccine Shipments Will Force Suspension of Shoo the Flu Clinics 2Health News:Children's National Experts Presenting at American Academy of Pediatrics Conference, 2
(Date:1/23/2015)... MONMOUTH JUNCTION, N.J. , Jan. 23, 2015 ... immunotherapy company commercializing its CytoSorb® extracorporeal cytokine adsorber ... surgery patients, announced the receipt of $385,642, net ... approved participant of the Technology Business Tax Certificate ...
(Date:1/23/2015)... LONDON and BOSTON , January ... structure-guided drug discovery and development company, is delighted to announce ... has been awarded to Miles Congreve (Vice President ... co-founder) and Malcolm Weir (Chief Executive Officer and ...
(Date:1/22/2015)... 22, 2015  BiOptix is pleased to announce the appointment ... of Chemistry and Biochemistry. Scott joins the company after previous ... Amgen throughout the course of his nearly 20 year ... is a nationally recognized thought leader in the biosensor ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4BiOptix Expands Leadership Team with the Appointment of Dr. Scott Klakamp as Vice President of Chemistry and Biochemistry 2
... Traditionally, when choosing a non-contact diagnostic lens, ... wide field of view and high magnification. ... introduced by Volk Optical, doctors can have both ... widest field of view available in a non-contact ...
... is a 3.0mm single loaded suture anchor ... anchor barb catches on the cancellous bone ... "breaks" free. The small size is perfect ... used in rotator cuff repair where single ...
... Tac™ implantThe USS Sports Medicine™ E-Z Tac implant ... soft tissue to bone. The resorbable repair device ... bone and is used to reattach damaged soft ... a resorbable copolymer, a polyester derivative of lactic ...
... Soft Tissue Anchor 2 mm is a resorbable ... bone using sutures. The resorbable repair device is ... and is used to reattach damaged soft tissue. ... copolymer, derived from glycolide and lactide colored with ...
Medicine Products: